-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $147

Benzinga·05/07/2025 14:24:17
Listen to the news
Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target from $176 to $147.